FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • October 18th, 2021 • Allarity Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledOctober 18th, 2021 Company IndustryThis First Amendment (“First Amendment”) to Exclusive License Agreement effective as of Dec,. 11 2020 (“First Amendment Effective Date”) is by and between: EISAI INC., with its principal office at 100 Tice Blvd., Woodcliff Lake, NJ 07093, United States of America (“Eisai”) and ALLARITY THERAPEUTICS A/S, with its principal office at Venlighedsvej I, DK-2970 Hoersholm, Denmark (“Allarity”)(formerly Oncology Venture A/S), with reference to the following:
LICENSE AGREEMENT between NOVARTIS PHARMA AG and ONCOLOGY VENTURE ApSLicense Agreement • October 18th, 2021 • Allarity Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 18th, 2021 Company Industry JurisdictionThis LICENSE AGREEMENT (“License Agreement”) is made as of the 6. day of April, 2018 (“Effective Date”), by and between Novartis Pharma AG, a company organized under the laws of Switzerland and located at Lichtstrasse 35, 4056 Basel, Switzerland (“Novartis”), and Oncology Venture ApS, a company organized under the laws of Denmark, with headquarters at Venlighedsvej 1, DK-2970 Hoersholm, Denmark (“OV”). Novartis and OV are each referred to individually as a “Party” and together as the “Parties.”
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.Development, Option and License Agreement • October 18th, 2021 • Allarity Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 18th, 2021 Company Industry JurisdictionTHIS DEVELOPMENT, OPTION AND LICENSE AGREEMENT (this “Agreement”) is made and entered into effective as of the 1st day of March, 2019 (the “Effective Date”)